Niacin: another look at an underutilized lipid-lowering medication

@article{Creider2012NiacinAL,
  title={Niacin: another look at an underutilized lipid-lowering medication},
  author={J. Creider and R. Hegele and T. Joy},
  journal={Nature Reviews Endocrinology},
  year={2012},
  volume={8},
  pages={517-528}
}
Niacin, or water-soluble vitamin B3, when given at pharmacologic doses, is a powerful lipid-altering agent. This drug, which lowers the levels of atherogenic, apolipoprotein-B-containing lipoproteins, is one of few medications that can raise the levels of atheroprotective HDL cholesterol. Niacin also has beneficial effects on other cardiovascular risk factors, including lipoprotein(a), C-reactive protein, platelet-activating factor acetylhydrolase, plasminogen activator inhibitor 1 and… Expand
Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?
  • M. Zeman, M. Vecka, +4 authors A. Žák
  • Medicine
  • Medical science monitor : international medical journal of experimental and clinical research
  • 2015
TLDR
The mechanisms underlying the hypolipidemic and antiatherogenic effects of niacin as well as some limitations of the designs of the AIM HIGH and HP2-THRIVE studies are analyzed and the possibilities of rational usage of niakin for specific types of dyslipidemias are provided. Expand
Pharmacological Effects of Niacin on Acute Hyperlipemia.
TLDR
The purpose of this review was to provide an update on effects and mechanisms related to the pharmacological actions of niacin on acute hyperlipemia. Expand
Nonstatin Low-Density Lipoprotein–Lowering Therapy and Cardiovascular Risk Reduction—Statement From ATVB Council
TLDR
As evidence for benefit in CVD prevention accumulates, it is anticipated that clinical practice will shift toward more assertive LDL-lowering treatment, using both statins and nonstatins initiated earlier in appropriately selected patients. Expand
Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH.
TLDR
The addition of ERN to simvastatin/ezetimibe had marginal effects on glycemia in those with diabetes at baseline, and there was a trend toward increased development of new-onset diabetes. Expand
Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib
TLDR
The ongoing large-scale, randomized–placebo, controlled-outcomes study with anacetrapib coadministered with statin treatment will not only test the hypothesis if CETP inhibition lowers residual CV risk but will also provide insight as to which patient subgroups might benefit the most from an acetrapib despite aggressive therapy with statins. Expand
Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol
  • R. Wright
  • Medicine
  • Current opinion in cardiology
  • 2013
TLDR
Pharmacological manipulation of HDL-C has not improved the cardiovascular outcomes and several agents have caused harm or unacceptable side-effects and further studies are needed before one can recommend the use of additional lipid-modifying therapies beyond statins. Expand
Niacin: an old lipid drug in a new NAD+ dress
TLDR
An alternative point of view is presented to explain niacin’s mechanism of action, with a strong focus on the importance of how this old drug acts as a control switch of NAD+/sirtuin-mediated control of metabolism. Expand
Targeting Lipoprotein (a): an Evolving Therapeutic Landscape
TLDR
Targeted Lp(a) reduction is certainly intriguing and will likely continue to be an active area of investigation in the future. Expand
Investigational therapies for the treatment of atherosclerosis
TLDR
This review discusses the new antisense oligotide inhibitor of apo B synthesis, mipomersen; pro-protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and cholesterol ester transport protein (CETP) inhibitors, which inhibit very-low-density lipoprotein production in the liver and chylomicron inhibition in the intestine. Expand
Vitamin supplements in type 2 diabetes mellitus management: A review.
TLDR
A review of the literature assessing the use of vitamins A, C, E, D, K and the B group vitamins in the management of type 2 diabetes mellitus found no clear evidence supporting the beneficial role of any specific vitamin in the treatment of T2DM. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 152 REFERENCES
New perspectives on the use of niacin in the treatment of lipid disorders.
TLDR
Niacin-induced changes in serum lipid levels produce significant improvements in both coronary artery disease and clinical outcomes, and is ideal for treating a wide variety of lipid disorders, including the metabolic syndrome, diabetes mellitus, isolated low high-density lipoprotein cholesterol, and hypertriglyceridemia. Expand
Safety considerations with niacin therapy.
TLDR
Clinical evidence since the introduction of statins do not support a general myopathic effect of niacin either alone or in combination with statins, and a valuable medication for cardiovascular risk is underused. Expand
Niacin in cardiovascular prevention: mechanisms, efficacy, and safety
  • J. Guyton
  • Medicine
  • Current opinion in lipidology
  • 2007
TLDR
Understanding of the mechanisms, efficacy, and safety of niacin, along with progress in reducing the chief side effect of flushing, should enhance the use of this valuable agent for cardiovascular prevention. Expand
Effects of niacin on glucose control in patients with dyslipidemia.
TLDR
On a population basis, significant reductions in incidences of cardiovascular events and the degree of atherosclerotic progression associated with long-term niacin (or niac in-statin) therapy in patients with diabetic dyslipidemia outweigh the typically mild effects of this therapy on glycemic regulation. Expand
Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy.
TLDR
It is demonstrated that full-dose niacin/moderate-dose simvastatin combination has sustained benefits on atherogenic apoB lipoproteins, at least comparable to high- dose simvastsatin, while also raising HDL-cholesterol. Expand
Nicotinic acid: A new look at an old drug
  • J. Farmer
  • Medicine
  • Current atherosclerosis reports
  • 2009
TLDR
Clinical trials utilizing clinical or angiographic end points demonstrated efficacy for the use of nicotinic acid in monotherapy or in combination with bile acid resins or statins. Expand
Extended-release niacin raises adiponectin and leptin.
TLDR
Short-term treatment with extended-release niacin causes a pronounced increase in adiponectin but fails to improve atheroprotective functions attributed to adiponECTin, such as insulin sensitivity, anti-inflammation and endothelial function. Expand
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
TLDR
Simvastatin plus niacin provides marked clinical and angiographically measurable benefits in patients with coronary disease and low HDL levels, and the use of antioxidant vitamins in this setting must be questioned. Expand
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
TLDR
Among patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of less than 70 mg per deciliter, there was no incremental clinical benefit from the addition of niacin to statin therapy during a 36-month follow-up period, despite significant improvements in HDL cholesterol and triglyceride levels. Expand
Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.
TLDR
Niacin therapy may be considered as an alternative to statin drugs or fibrates for patients with diabetes in whom these agents are not tolerated or fail to sufficiently correct hypertriglyceridemia or low HDL-C levels. Expand
...
1
2
3
4
5
...